Authors: Fayer, JL Zannikos, PN Stevens, JC Luo, YQ Sidhu, R Kirkesseli, S

Citation: Jl. Fayer et al., Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-gamma agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity, J CLIN PHAR, 41(3), 2001, pp. 305-316

Authors: Rohatagi, S Calic, F Harding, N Ozoux, ML Bouriot, JP Kirkesseli, S DeLeij, L Jensen, BK

Citation: S. Rohatagi et al., Pharmacokinetics, pharmacodynamics, and safety of inhaled cyclosporin A (ADI628) after single and repeated administration in healthy male and female subjects and asthmatic patients, J CLIN PHAR, 40(11), 2000, pp. 1211-1226

Authors: Zannikos, PN Rohatagi, H Jensen, BK DePhillips, SL Massignon, D Calic, F Sibille, M Kirkesseli, S

Citation: Pn. Zannikos et al., Pharmacokinetics, pharmacodynamics, and safety of a platelet GPIIb/IIIa antagonist, RGD891, following intravenous administration in healthy male volunteers, J CLIN PHAR, 40(11), 2000, pp. 1245-1256

Authors: Le Liboux, A Cachia, JP Kirkesseli, S Gautier, JY Guimart, C Montay, G Peeters, PAM Groen, E Jonkman, JHG Wemer, J

Citation: A. Le Liboux et al., A comparison of the pharmacokinetics and tolerability of riluzole after repeat dose administration in healthy elderly and young volunteers, J CLIN PHAR, 39(5), 1999, pp. 480-486